Lynch D H, Miller R E
Immunex Corporation, Seattle, WA 98101.
J Immunol. 1990 Sep 15;145(6):1983-90.
The data demonstrate that IL-7, a cytokine that was originally identified, purified, and cloned based upon its ability to support the growth of pre-B cells in vitro, also induces proliferation and promotes the generation of lymphokine-activated killer (LAK) cell activity in populations of resting peripheral lymphoid cells. Although the kinetics of LAK induction by IL-7 (which peaked at days 6 to 8 of culture) was slower than that detected in cultures containing IL-2 (which peaked at day 4), IL-7 was significantly more effective at maintaining cytotoxic activity over longer periods of time, and greater viable cell recoveries, than was IL-2. A wide range of murine tumor target cells were found to be lysed in an MHC-unrestricted fashion by IL-7 induced LAK, but syngeneic Con A-induced lymphoblasts were not; nor were target cells from the human tumors K562 or Daudi lysed by IL-7 LAK. IL-7 LAK were induced in populations of lymphoid cells obtained from secondary lymphoid tissues (peripheral lymph nodes and spleen), but not from primary lymphoid tissues (thymus and bone marrow). LAK induced by IL-7 from unfractionated populations of lymphoid cells were completely eliminated by treatment with anti-CD8 or anti-Thy-1+C, and unaffected by treatment with anti-CD4, anti-asialo GM1 or anti-NK1.1+C. Interestingly, although no detectable CD4+ effector cells could be detected in populations of LAK generated from unfractionated populations of lymphoid cells stimulated by IL-7, they were found to be generated from populations of lymphoid cells from which CD8+ cells had been eliminated before being cultured in medium containing IL-7. These data suggest that CD4+ T cells do not normally give rise to IL-7-induced LAK unless they are first separated from CD8+ T cells. LAK induced by IL-7 appear to be distinct from LAK activity induced by IL-2 in that there is no detectable involvement of NK-like effector cells at either the precursor or effector cell stages.
数据表明,白细胞介素-7(IL-7)这种细胞因子最初是根据其在体外支持前B细胞生长的能力而被鉴定、纯化和克隆的,它还能诱导静息外周淋巴细胞群体增殖并促进淋巴因子激活的杀伤(LAK)细胞活性的产生。尽管IL-7诱导LAK的动力学过程(在培养第6至8天达到峰值)比含IL-2的培养物中检测到的要慢(在第4天达到峰值),但在较长时间内维持细胞毒性活性方面,IL-7比IL-2显著更有效,且活细胞回收率更高。发现多种小鼠肿瘤靶细胞能被IL-7诱导的LAK以MHC非限制性方式裂解,但同基因伴刀豆球蛋白A诱导的淋巴母细胞则不能;来自人肿瘤K562或Daudi的靶细胞也不会被IL-7 LAK裂解。IL-7 LAK是在从二级淋巴组织(外周淋巴结和脾脏)获得的淋巴细胞群体中诱导产生的,而不是从一级淋巴组织(胸腺和骨髓)中产生。用抗CD8或抗Thy-1 + C处理可完全消除由未分级淋巴细胞群体中的IL-7诱导的LAK,而用抗CD4、抗去唾液酸GM1或抗NK1.1 + C处理则无影响。有趣的是,尽管在由IL-7刺激的未分级淋巴细胞群体产生的LAK群体中未检测到可检测到的CD4 + 效应细胞,但发现它们是从在含IL-7的培养基中培养前已去除CD8 + 细胞的淋巴细胞群体中产生的。这些数据表明,CD4 + T细胞通常不会产生IL-7诱导的LAK,除非它们首先与CD8 + T细胞分离。IL-7诱导的LAK似乎与IL-2诱导的LAK活性不同,因为在前体或效应细胞阶段均未检测到NK样效应细胞的参与。